The Food and Drug Administration on Monday approved Merck's new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia, a spokesperson for the drugmaker said.Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to pneumonia. It's the first pneumococcal conjugate vaccine designed speci ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference. My name is Chris Shibutani. And on behalf of the entire Go ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference. My name is Chris Shibutani. And on behalf of the entire Go ...

Nudphon PhuengsuwanIntroduction I usually spend my mornings browsing various news outlets. This was part of a prior job where I provided daily macro and geopolitical newsletters for both private and institutional clients. This includes American, German, French, Italian, and newspapers from other regions. I use translation for most of these (except English, Dutch, and German languages). I mainly do this to get a good overview of what is happening across the world and how this could impact the stocks that ...

That's not a bad crowd to follow when investing in stocks.Many billionaires are active on Wall Street and largely built their wealth that way. So, paying attention to their moves and the stocks they invest in can teach us a lot. Of course, blindly following the lead of anyone -- billionaire or not -- isn't an advisable strategy when looking to grow wealth. It's essential to do some research of our own.With that said, let's look at two dividend stocks that at least a couple of billionaires bought during the ...

Merck (MRK) closed the latest trading day at $129.45, indicating a +0.57% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.19%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 1.96%.Prior to today's trading, shares of the pharmaceutical company had lost 1.28% over the past month. This has lagged the Medical sector's gain of 3.54% and the S&P 500's gain of 3.35% in that time.The investment community wi ...

Merck & Co., Inc. (NYSE:MRK) Investor Event at ASCO 2024 June 3, 2024 7:00 PM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Dean Li - President of Merck Research Labs Eliav Barr - Chief Medical Officer & Head of Global Clinical Development Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Joanne Monahan - Senior Vice President, US Oncology Conference Call Participant ...

Merck & Co., Inc. (NYSE:MRK) Investor Event at ASCO 2024 June 3, 2024 7:00 PM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Dean Li - President of Merck Research Labs Eliav Barr - Chief Medical Officer & Head of Global Clinical Development Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Joanne Monahan - Senior Vice President, US Oncology Conference Call Participant ...

Merck (MRK) announced a definitive agreement to acquire London-based private biotech Eyebiotech Limited (“EyeBio”), which makes therapies for retinal diseases. The buyout will expand Merck’s presence in the growing ophthalmology market. The acquisition will add EyeBio’s lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases like diabetic macular edema (DME) and neovascular age-related macular degeneration in a phase Ib/IIa study called AMARONE. In Febru ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...